Caelyx
Caelyx is a pegylated liposomal formulation of the anthracycline cytotoxic drug doxorubicin, administered intravenously to treat cancer.
Caelyx is a pegylated liposomal formulation of the anthracycline cytotoxic drug doxorubicin, administered intravenously to treat cancer. The doxorubicin it carries acts inside dividing cells by intercalating into DNA and poisoning topoisomerase II, generating double-strand breaks, and by producing reactive oxygen species that damage DNA, lipids, and proteins; the accumulated damage drives apoptosis through pathways regulated by Bcl-2 family proteins. Enclosing the drug in long-circulating liposomes does not alter this molecular mechanism but changes its distribution: the carrier prolongs circulation, lowers peak free-drug exposure, and favors accumulation in tumors with leaky vasculature, which underlies its reduced cardiotoxicity relative to conventional doxorubicin.
Clinically, Caelyx and related liposomal doxorubicin products are used across solid and hematologic cancers and are frequently combined with other cytotoxics — taxanes such as nab-paclitaxel and docetaxel, along with gemcitabine or oxaliplatin — and with radiotherapy. Much current research treats liposomal doxorubicin as a reference nanomedicine against which newer carriers are measured, including aptamer-functionalized liposomes, hybrid nanogels, functionalized carbon dots, polymeric micelles, and stimulus-responsive lipid nanoparticle, and uses it to probe the delivery barriers that limit chemotherapy: dense extracellular matrix laid down by cancer-associated fibroblasts, elevated interstitial pressure in the tumor microenvironment, and poor penetration into fibrotic tissue such as that of hepatocellular carcinoma. Stromal enzymes including MMP-9 and fibroblast activation protein are exploited to trigger drug release within the tumor, while chitosan-based and nucleoside-transporter-directed carriers aim to make doxorubicin orally absorbable by evading p-glycoprotein efflux and CYP3A4 metabolism. Resistance to doxorubicin, whether free or liposomal, is attributed largely to drug efflux, altered redox homeostasis, and blunted apoptotic signaling.
Where the papers sit
11 papers from the last 6 months study caelyx directly · updated from PubMed 11 Nov 2026
Study type 1 clinical trial · 10 preclinical
Themes 3 themes
-
Doxorubicin Delivery and Combination Therapy
Doxorubicin therapy is moving toward engineered carriers and combination regimens that improve penetration while limiting systemic toxicity. FAP-responsive nanoparticles remodel fibrotic stroma in hepatocellular carcinoma, and carbon dots or liposomes provide controlled delivery. Photothermal treatment and nab-paclitaxel are recurring partners, with evidence spanning preclinical models and a phase II study in adenoid cystic carcinoma. Manufacturing scale-up and clinical validation remain open challenges.
5 papers · 45.5%
-
Multifunctional Nanocarrier Drug Delivery
Multifunctional nanocarriers are being developed to improve doxorubicin delivery, tumor penetration and treatment selectivity. Aptamer-functionalized liposomes, chitosan micelles and injectable hydrogels combine targeting with controlled or self-amplified release. Galectin-3 targeting provides a route to tumor-associated molecular recognition, while oral formulations address absorption limits. Photochemotherapy and theranostic designs broaden delivery beyond conventional systemic dosing.
4 papers · 36.4%
-
Sialic Acid-Targeted Nanotherapy
Sialic acid overexpression is being exploited to concentrate nanotherapeutics in cancer cells while combining cytotoxic and immune-modulating effects. Polymerized polyphenol-decorated cationic complexes target breast cancer cells, whereas hybrid nanogels deliver doxorubicin and zinc to sialic acid-rich lung cancers. Hyaluronic acid, alginate and N-acetyl-β-neuraminic acid recur as components of the targeting or carrier chemistry. Reported progress centers on selective uptake and lower inhibitory concentrations, but broader validation remains needed.
2 papers · 18.2%
Papers
The 11 papers from the last 6 months that study caelyx directly, newest first, by theme and by study type. Study types come from PubMed publication types and MeSH headings.
By theme
Doxorubicin Delivery and Combination Therapy (5)
- FAP-α-Responsive Size-Transformable Lipid Nanoparticles for Stromal Remodeling and Enhanced Drug Penetration in Fibrotic Hepatocellular Carcinoma. ACS applied materials & interfaces · 22 Jun 2026 PMID 42328782
- Engineering functionalized carbon dots as biocompatible nanocarriers for controlled doxorubicin delivery in cancer therapy. Journal of materials chemistry. B · 16 Jun 2026 PMID 42300585
- Liposomal doxorubicin plus nab-paclitaxel with/without chemoradiotherapy in head and neck adenoid cystic carcinoma: single-arm phase II study. Signal transduction and targeted therapy · 12 Jun 2026 PMID 42285940
- Microfluidic-active loading integration enables rapid two-step manufacturing of antibiotic-loaded liposomes with intravesicular drug nanocrystallization. International journal of pharmaceutics · 10 Jun 2026 PMID 42269791
- Enhanced Therapeutic Efficacy of Combined Photothermal Therapy and Doxorubicin Chemotherapy in Anaplastic Thyroid Carcinoma: An Innovative Treatment Approach. Molecular pharmaceutics · 4 Jun 2026 PMID 42243048
Multifunctional Nanocarrier Drug Delivery (4)
- Engineering Coil-Coiled Domains for the Design of Modular Theranostic Agents: Galectin-3 as a Targeting Moiety. Biomacromolecules · 27 Jun 2026 PMID 42363882
- Photocage Prodrug Coupled with Injectable Hydrogel for Self-Amplified Photochemotherapy. Journal of medicinal chemistry · 26 Jun 2026 PMID 42358122
- Aptamer-Functionalized Liposome Delivery System Based on Multifunctional Microreactor Design. ACS applied materials & interfaces · 24 Jun 2026 PMID 42339546
- Multi-functional purine nucleoside-modified chitosan polymer micelles for improving the oral absorption of doxorubicin based on nucleoside transporter mediation. International journal of pharmaceutics · 14 Jun 2026 PMID 42289209
Sialic Acid-Targeted Nanotherapy (2)
- Targeted hybrid nanogels for sialic acid-overexpressing lung cancers: DNA-mediated chelation of doxorubicin and adsorption of zinc ions. International journal of biological macromolecules · 11 Jun 2026 PMID 42276469
- Polymerized Polyphenol-Decorated Cationic Hydroxyethylcellulose Nanocomplexes for Enhanced Breast Cancer Cell Killing Effects. Biomacromolecules · 28 May 2026 PMID 42210019
By study type
Clinical trials (1)
- Liposomal doxorubicin plus nab-paclitaxel with/without chemoradiotherapy in head and neck adenoid cystic carcinoma: single-arm phase II study. Signal transduction and targeted therapy · 12 Jun 2026 PMID 42285940
Preclinical: animal, cell and lab studies (10)
- Engineering Coil-Coiled Domains for the Design of Modular Theranostic Agents: Galectin-3 as a Targeting Moiety. Biomacromolecules · 27 Jun 2026 PMID 42363882
- Photocage Prodrug Coupled with Injectable Hydrogel for Self-Amplified Photochemotherapy. Journal of medicinal chemistry · 26 Jun 2026 PMID 42358122
- Aptamer-Functionalized Liposome Delivery System Based on Multifunctional Microreactor Design. ACS applied materials & interfaces · 24 Jun 2026 PMID 42339546
- FAP-α-Responsive Size-Transformable Lipid Nanoparticles for Stromal Remodeling and Enhanced Drug Penetration in Fibrotic Hepatocellular Carcinoma. ACS applied materials & interfaces · 22 Jun 2026 PMID 42328782
- Engineering functionalized carbon dots as biocompatible nanocarriers for controlled doxorubicin delivery in cancer therapy. Journal of materials chemistry. B · 16 Jun 2026 PMID 42300585
- Multi-functional purine nucleoside-modified chitosan polymer micelles for improving the oral absorption of doxorubicin based on nucleoside transporter mediation. International journal of pharmaceutics · 14 Jun 2026 PMID 42289209
- Targeted hybrid nanogels for sialic acid-overexpressing lung cancers: DNA-mediated chelation of doxorubicin and adsorption of zinc ions. International journal of biological macromolecules · 11 Jun 2026 PMID 42276469
- Microfluidic-active loading integration enables rapid two-step manufacturing of antibiotic-loaded liposomes with intravesicular drug nanocrystallization. International journal of pharmaceutics · 10 Jun 2026 PMID 42269791
- Enhanced Therapeutic Efficacy of Combined Photothermal Therapy and Doxorubicin Chemotherapy in Anaplastic Thyroid Carcinoma: An Innovative Treatment Approach. Molecular pharmaceutics · 4 Jun 2026 PMID 42243048
- Polymerized Polyphenol-Decorated Cationic Hydroxyethylcellulose Nanocomplexes for Enhanced Breast Cancer Cell Killing Effects. Biomacromolecules · 28 May 2026 PMID 42210019
Written from 11 PubMed abstracts, each one listed by PMID above. Published: 2026-06-16. Last written: 2026-08-26 by GPT. Reviewed by a human editor on 2026-07-24. Drafted by language models from published abstracts; not medical advice.